Strs Ohio Acquires Shares of 45,400 Chimerix, Inc. (NASDAQ:CMRX)

Strs Ohio acquired a new stake in Chimerix, Inc. (NASDAQ:CMRXGet Rating) during the third quarter, Holdings Channel reports. The fund acquired 45,400 shares of the biopharmaceutical company’s stock, valued at approximately $87,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Chimerix by 14.2% in the 1st quarter. State Street Corp now owns 4,561,868 shares of the biopharmaceutical company’s stock valued at $20,893,000 after purchasing an additional 568,498 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Chimerix by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 3,832,252 shares of the biopharmaceutical company’s stock worth $17,552,000 after acquiring an additional 105,441 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Chimerix by 11.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,951,521 shares of the biopharmaceutical company’s stock worth $8,938,000 after acquiring an additional 206,990 shares during the period. Monaco Asset Management SAM purchased a new position in shares of Chimerix during the 2nd quarter worth $3,077,000. Finally, Penn Capital Management Company LLC purchased a new position in shares of Chimerix during the 2nd quarter worth $1,764,000. Hedge funds and other institutional investors own 58.03% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded Chimerix from a “hold” rating to a “buy” rating in a report on Friday, November 4th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Chimerix has a consensus rating of “Buy” and an average price target of $8.50.

Chimerix Trading Up 0.5 %

Shares of CMRX opened at $1.83 on Friday. The firm has a market cap of $161.12 million, a P/E ratio of 1.05 and a beta of 1.17. Chimerix, Inc. has a 12-month low of $1.27 and a 12-month high of $6.43. The company’s 50-day moving average price is $2.02 and its 200 day moving average price is $2.08.

Chimerix (NASDAQ:CMRXGet Rating) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.10 by $0.65. The firm had revenue of $32.56 million for the quarter, compared to analyst estimates of $205.30 million. Chimerix had a net margin of 464.75% and a return on equity of 147.04%. Equities research analysts forecast that Chimerix, Inc. will post 1.97 earnings per share for the current year.

About Chimerix

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Further Reading

Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRXGet Rating).

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.